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Abstract
Background: Progressive loss of articular cartilage is a central hallmark in many joint disease, however,
the relative importance of individual proteolytic pathways leading to cartilage erosion is at present
unknown. We therefore investigated the time-dependant release ex vivo of MMP- and aggrecanase-derived
fragments of aggrecan and type II collagen into the supernatant of bovine cartilage explants cultures using
neo-epitope specific immunoassays, and to associate the release of these fragments with the activity of
proteolytic enzymes using inhibitors.
Findings: Bovine cartilage explants were cultured in the presence or absence of the catabolic cytokines
oncostatin M (OSM) and tumor necrosis factor alpha (TNFα). In parallel, explants were co-cultured with
protease inhibitors such as GM6001, TIMP1, TIMP2 and TIMP3. Fragments released into the supernatant
were determined using a range of neo-epitope specific immunoassays; (1) sandwich 342FFGVG-G2 ELISA,
(2) competition NITEGE373ELISA (3) sandwich G1-NITEGE373 ELISA (4) competition 374ARGSV ELISA, and
(5) sandwich 374ARGSV-G2 ELISA all detecting aggrecan fragments, and (6) sandwich CTX-II ELISA,
detecting C-telopeptides of type II collagen. We found that (1) aggrecanase-derived aggrecan fragments
are released in the early (day 2-7) and mid phase (day 9-14) into the supernatant from bovine explants
cultures stimulated with catabolic cytokines, (2) the release of NITEGE373 neo-epitopes are delayed
compared to the corresponding 374ARGSV fragments, (3) the MMP inhibitor GM6001 did not reduce the
release of aggrecanase-derived fragment, but induced a further delay in the release of these fragments, and
finally (4) the MMP-derived aggrecan and type II collagen fragments were released in the late phase (day
16-21) only.
Conclusion: Our data support the model, that aggrecanases and MMPs act independently in the
processing of the aggrecan molecules, and furthermore that suppression of MMP-activity had little if any
effect on the quantity of aggrecanase-derived fragments released from explants cultures.
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All though the pathogenesis joint diseases is not fully
understood, major efforts have been allocated to the
development of drugs aimed at down regulating proteases
expression and acitivity involved in the degradation of the
extracellular matrix of the joint. The protease repertoire of
the chondrocytes is wide, and both aggrecanases, MMPs,
and cathepsins have been associated with degradation
and/or repair of the ECM of the articular cartilage in the
joint [1-7].
To study the metabolic events leading to joint damage,
cultures of articular cartilage has been a useful model sys-
tem [5,8-12]. In bovine explants cultures stimulated with
catabolic cytokines it has been demonstrated that both
aggrecan and collagen fragments are released into the
supernatant [5,13-15] and that inhibition of MMP-activ-
ity causes a suppression of both proteoglycan and type II
collagen degradation [6]. However, release of aggreca-
nase-derived aggrecan fragments in explants cultures in
the presence of protease-inhibitors have until now not
been monitored by neo-epitope specific immunoassays.
The present study was initiated to develop and character-
ize new immunoassays for the quantitative detection of
aggrecanase-derived aggrecan fragments carrying neo-
epitopes in the interglobular domain of aggrecan, and to
compare these tests to the MMP-derived aggrecan profile
obtained from ex vivo cultures of bovine articular carti-
lage.
Materials and methods
Bovine articular cartilage explants
The stifle joints from young heifers were received from the
local slaughterhouse, and cartilage explants were isolated
and cultured essentially as described before [6], with pro-
tease inhibitor GM6001 used at 10 μM, and TIMP-1,
TIMP-2, and TIMP-3 used at 50 ng/ml.
Biochemical markers of aggrecan and collagen
a) Aggrecanase-derived aggrecan fragments carrying 374ARGSV 
(374ARGSV ELISA)
Monoclonal antibody 6D6 was developed by immunizing
mice with synthetic peptide ARGSVILTVK-GGC conju-
gated to ovalbumin and performing fusion by standard
techniques. MAb 6D6 was selected as it recognised the
homologous sequence (ARGSVILTVK) but not the N-ter-
minally elongated sequence GEARGSVILTVK.
A competition assay was designed by adding a ARGS-
VILTVK-GGC-biotin solution to streptavidin-coated
microtitre plates. After washing three times, wells were
incubated with 50 μL of supernatant prediluted in buffer
and 100 μL prediluted 6D6 for 1 hour at 20°C with shak-
ing. The plates were washed and incubated with peroxi-
dase-conjugated, goat anti-mouse immunoglobulin,
washed, and subsequently incubated for 15 minutes with
TMB. The colour reaction was stopped and the absorbance
was measured at 450 nm with 650 nm as reference.
b) Aggrecanase-derived aggrecan fragments carrying 374ARGSV and 
G2 (374ARGSV-G2 ELISA)
This sandwich assay was in principle as the 374ARGSV-G2
ELISA previously described [16] except that the capture
antibody BC-3 was replaced with MAb 6D6.
c) Aggrecanase-derived aggrecan fragments carrying NITEGE373 
(NITEGE373 ELISA)
Spleen cells from mice immunized with CPLPRNITEGE373
conjugated in the N-terminus to KLH was used for fusion
and development of monoclonal antibodies recognizing
the aggrecan neo-epitope NITEGE373. MAb 1H11 was
used for test development, as it did not recognize the elon-
gated amino acid sequence PLPRNITEGEAR demonstrat-
ing specificity for the neo-epitope. A competition ELISA
similar to the 374ARGSV ELISA described above was devel-
oped using MAb 1H11.
d) Aggrecanase-derived aggrecan fragments carrying NITEGE373 and 
G1 (G1-NITEGE373 ELISA)
Similar to the 374ARGSV-G2 ELISA described above except
that biotinylated MAb 1H11 used as capture antibody.
e) MMP-derived aggrecan fragments carrying 342FFGVG and G2 
(342FFGVG-G2 ELISA)
This immunoassay has previously been described [16].
f) MMP-derived type II collagen fragments carrying EKGPDP (CTX-II 
ELISA)
These collagen fragments were detected by the Serum PC
CartiLaps ELISA [17] according to instructions of the man-
ufacturer (IDS, UK).
Results
Tests for aggrecan fragments
To be able to monitor the degradation of the ECM and to
link the release of closely associated protein fragments
with the activity of certain proteases, it was decided to
develop monoclonal antibodies to the neo-epitopes orig-
inating from the major aggrecanase site in aggrecan. Some
of these neo-epitope specific antibodies have been
described previously [16], but in the present study we
report the development of MAb 1H11 recognising the
neo-epitope NITEGE373 and MAb 6D6 binding to
374ARGSV. Both neo-epitope sequences originate from the
cleavage of aggrecan by aggrecanases at the amino acid
sequence NITEGE373-374ARGSV.
MAb 1H11 and MAb 6D6 were incorporated into compet-
itive immunoassays as well as sandwich assays with MAbPage 2 of 8
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in both the G1 and the G2 domain [16], thereby making
it useful in sandwich constructions with antibodies bind-
ing to neo-epitopes in the interglobular domain (figure
1).
The basic characteristics of each (new) assay are summa-
rized in table 1. It should be noted, that calibrator mate-
rial was different in the competition and the sandwich
assays, i.e. synthetic peptides vs ADAMTS-4 treated bovine
aggrecan, and therefore absolute values cannot be com-
pared.
The technical performance data was obtained by testing of
supernatants originating from bovine cartilage explants
cultures, and to support these data, bovine synovial fluid
was tested in each of the tests. In bovine synovial fluid (n
= 7), concentrations of the four analytes were; NITEGE373,
335-490 ng/ml; G1-NITEGE373, 371-866 μg/ml;
374ARGSV, <5 ng/ml; and 374ARGSV-G2, 23-49 μg/ml.
Subsequently, these immunoassays were included in a
portfolio of neo-epitope specific immunoassays used for
profiling supernatants of explants cultures.
Aggrecan and collagen fragments released from explants cultures 
with and without protease inhibitors
When bovine explants cultures were stimulated with OSM
and TNFα, the release of aggrecan fragments carrying the
neo-epitope 374ARGSV generated by aggrecanase activity
were rapidly detected by both the 374ARGSV competitive
ELISA (figure 2A) and the 374ARGSV sandwich ELISA (fig-
ure 2B). Quantitating and accumulating the release of
fragments in the three different phases, i.e. early phase day
0-7, mid phase day 9-14, and late phase day 16-21, indi-
cate that 70, 25, and 5% of the measured fragments are
released in the early, mid, and late phase, respectively, in
the 374ARGSV competitive ELISA (figure 3A). Co-incuba-
tion with the MMP-inhibitor GM6001 induced a delay in
the release of these aggrecan fragments to 47, 49, and 4%
of the fragments being detected by the 374ARGSV compet-
itive ELISA (figure 3A) in the early, mid and late phase,
respectively. The accumulated release of the fragments
detected by the 374ARGSV competitive ELISA over the 21
days was 10.7-12.6% lower with inhibitor, which was not
significant.
In contrast, the OSM/TNFα-stimulated release of frag-
ments carrying the NITEGE373 neo-epitopes extended into
the mid phase, with a second peak around day 9-12 for
the two assays (figure 2C and 2D). The GM6001 induced
a further delay in release of the fragments carrying the
NITEGE373 neo-epitopes, and a clear single peak profile in
mid phase was observed in these supernatants (figure 2C
and 2D). Again, we did not observe significant changes in
the accumulated release of fragments for this and the cor-
responding sandwich assay.
The cytokine stimulated release of MMP-derived frag-
ments generated a completely different profile (figure 4A
and 4B), and in addition, the release of these fragments
remained undetected in the presence of GM6001.
At study termination alamar blue data confirmed cell via-
bility in all explants cultures except metabolic inactivated
(data not shown).
In parallel to these studies, the association between the
release profile and the activity of other protease families
were investigated by co-culturing the OSM and TNFα
stimulated bovine explants in the presence of TIMP1,
TIMP2, and TIMP3.
Across three experiments, none of these inhibitors
induced a consistent suppression (or stimulation) of
release of fragments into the supernatants (data not
shown).
Discussion
The study of metabolic processing of articular cartilage has
traditionally relied on measurements of glycosamino gly-
cans, hydroxyproline, isotope release etc [14], and
recently neo-epitope specific antibodies and immu-
noassays have stimulated the research in this area
Epitope-specificity of monoclonal antibodies binding to aggre-can fragmentsFigu  1
Epitope-specificity of monoclonal antibodies binding 
to aggrecan fragments. Schematic representation of the 
monoclonal antibodies selected for incorporation into immu-
noassays for quantification of aggrecan fragments carrying 
neo-epitopes. MAb F78 recognises a repeated epitope in the 
G1 and G2 domain, MAb AF28 binds to the MMP-derived 
neo-epitope 342FFGFG, MAb 1H11 binds the neo-epitope 
NITEGE373, and MAb 6D6 binds to 374ARGSV.Page 3 of 8
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Table 1: Summary of technical performance of four neo-epitope specific immunoassays
Parameter NITEGE373 G1-NITEGE373 374ARGSV 374ARGSV-G2
Measuring range (ng/ml) 12.3 - 1000 120 - 4000 0.4 - 20 16.5 - 1000
Lower detection limit (ng/ml) 4.1 40.1 0.1 5.5
Intraassay variation (CV, %) 4.2 - 9.6 4.0 - 6.0 7.4 - 11.2 2.0 - 3.5
Interassay variation (CV, %) 7.1 - 13.2 7.5 - 13.4 9.9 - 12.4 8.9 - 10.3
Dilution recovery (mean; range,%) 103.6;
88.9 - 118.2
106.6;
94.6 - 119.2
101.4;
89.3 - 117.1
93.4;
82.7 - 103.5
Specificity (%) PLPRNITEGE; 100
PLPRNITEGEAR; <0.1
ARGSVILTVK; <0.1
ARGSVILTVK; 100
GEARGSVILTVK; <0.1
PLPRNITEGE; <0.1
Aggrecanase-derived aggrecan fragments released into the supernatant from cartilage explants stimulated with catabolic cytokinesFigure 2
Aggrecanase-derived aggrecan fragments released into the supernatant from cartilage explants stimulated 
with catabolic cytokines. Bovine articular cartilage explants were stimulated with catabolic cytokines OSM and TNFα in the 
absence (open circles) and presence (closed circles) of the MMP-inhibitor GM6001. For comparison, parallel cultures were 
incubated with vehicle (continous line, no symbols) or metabolic inactivated at start by freeze-thaw cycles (dashed line). Super-
natants were collected every second or third day and tested in competition 374ARGSV ELISA (figure 2A), sandwich 374ARGSV-
G2 ELISA (figure 2B), competition NITEGE373 ELISA (figure 2C) and sandwich G1-NITEGE373 ELISA (figure 2D).
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the MMPs and the aggrecanases in the degradation and
repair of the extracellular matrix a broader portfolio of
reliable analytical techniques is required.
We report here the development of four corresponding
immunoassays all of which recognizes the neo-epitopes
being generated by the aggrecanses at the NITEGE373-
374ARGSV site. The application of these four tests allows
the quantitative assessment of closely related pools of
aggrecan fragments generated by aggrecanase, and further-
more we have compared the release-profile of these mol-
ecules to corresponding MMP-derived fragments.
Aggrecan profiling in bovine explants supernatants
Under various experimental conditions up to nine differ-
ent cleavage sites have been identified in the IGD, how-
ever, only two of these appear to occur in human tissue in
vivo, i.e. the MMP-derived VDIPEN341-342FFGVG and the
aggrecanase-derived NITEGE373-374ARGSV [7]. The charac-
terization of the proteolytic degradation of cartilage by
MMPs and aggrecanases was first described in the early
1990's [5,20-22], and since then, the relative importance
of MMPs and aggrecanases in aggrecanolysis have been
the subject of many studies.
Struglics and coworkers [23] identified at least nine differ-
ent GAG-containing aggrecan fragments in human syno-
vial fluid, with the 342FFGVG and 374ARGSV neo-epitopes
contributing 80% of the total pool of aggrecan fragments.
These and other observations led them to suggest that the
degradation of aggrecan occur by at least two independent
proteolytic pathways generating both 342FFGVG (the
MMP-mediated) and 374ARGSV-fragments (the aggreca-
nase-mediated).
The data reported in the present study, which originates
from a completely different experimental set up, is con-
sistent with this model. Both types of neo-epitopes have
been identified in the supernatants, however, their release
is separated in time as we never find MMP- and aggreca-
nase-derived neo-epitope fragment in the same superna-
tant.
The delay in the release of the fragments carrying the
NITEGE373neo-epitopes, compared to 374ARGSV frag-
ments, i.e with 70% and 41% of the analytes released after
the early phase, respectively, could be due to the anchor-
ing of the aggrecan molecule through the G1 domain and
the link protein to central hyaluronic acid filaments in the
ECM [24]. Linking of the 374ARGSV neo-epitope to the
Aggrecanase-derived aggrecan fragments released during the early, mid and late phase of cartilage explants stimulated with cat-abolic cytokinesFigure 3
Aggrecanase-derived aggrecan fragments released during the early, mid and late phase of cartilage explants 
stimulated with catabolic cytokines. As for figure 2, but release of fragments in the early (day 2-7, black bar), mid phase 
(day 9-14, dark grey bar) and late phase (day 16-21, light grey bar) are expressed in percentage of accumulated release during 
the 21 day study period.Page 5 of 8
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through the action of MMPs, which would cleave at the
VDIPEN341-342FFGVG intersection. We have seen no evi-
dence of MMP activity (to the extent this produces neo-
epitopes in aggrecan and type II collagen) and therefore is
consistent with the linking of G1 to HA/LINK. Also, link-
ing to ECM has not been associated with the other globu-
lar domains, i.e. G2 and G3.
Further delays in release of aggrecanase-derived fragments 
induced by the MMP-inhibitor GM6001, but not overall 
reduction
Others have reported the application of neo-epitope spe-
cific immunoassays for quantitative detection of aggrecan
fragments [5,16,25,26], however, this is the first report on
the application of neo-epitope specific immunoassays for
profiling of supernatants originating from explants cul-
tured in the presence of protease-inhibitors.
First, it is important to establish, that GM6001 did not
induce suppression of the overall release of the aggreca-
nase-derived aggrecan fragments, but merely delayed the
release of these proteolytic fragments. The molecular
mechanism behind this delay in the release of aggreca-
nase-derived fragments, which is influenced by MMP-
activity, remains to be determined. However, it could be
speculated that the effect of the MMPs in the early phase
is indirect, i.e. does not generate detectable neo-epitopes
in aggrecan and type II collagen, but act on other molecu-
lar structures which indirectly affects the release of these
neo-epitopes into the supernatants.
It should be noted, that the explant model system, which
requires molecular diffusion from inside of the explant to
the surface of the cartilage surface, is highly dependent on
the architecture of the tissue. Chondrocytes embedded in
the cartilage will respond metabolically to cytokine stim-
Release of aggrecan- and type II collagen-derived fragments from cartilage explants stimulated with catabolic cytokinesFigur 4
Release of aggrecan- and type II collagen-derived fragments from cartilage explants stimulated with catabolic 
cytokines. Supernatants from the experiment described in figure 2 was investigated in the sandwich 342FFGVG-G2 ELISA (fig-
ure 4A), the sandwich CTX-II ELISA measuring C-telopeptide fragments of type II collagen (figure 4B), sGAG (figure 4C) and 
hydroxyproline (figure 4D).Page 6 of 8
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structural integrity of the tissue. Therefore, at the macro-
scopically level the structure of the explants is an impor-
tant determinant of the release of fragments into the
culture supernatants. In addition to MMPs, aggrecanases,
and hyaluronidases, recent reports suggest m-calpain is
important in mature bovine articular cartilage [27].
Surprisingly, we failed to detect a consistent effect of the
aggrecanase inhibitors. Aggrecanase 1 (also called
ATAMTS-4) and aggrecanase 2 (also called ADAMTS-5)
are potent proteases capable of cleaving aggrecan at the
373-374 site [28], and we had expected at least TIMP3,
which has been reported to inhibit the activity of both
ADAMTS-4 and ADAMTS-5 [29,30], to suppress the
release of the aggrecanase-derived fragments.
Conclusion
We conclude that our data support the model that aggre-
canases and MMPs act independently in the processing of
the aggrecan molecules, and furthermore that suppression
of MMP-activity have little if any effect on the quantity of
aggrecanase-derived fragments released from explants cul-
tures.
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